DLH Achieves Leading Information Security Management Accreditation

2 years ago

Follows Previously Announced FedRAMP Authorization in Validating DLH’s Commitment to Best-in-Class Information Security and Data Management ServicesATLANTA, April 04, 2022…

RECELL® System Data to be Presented at the American Burn Association Annual Meeting

2 years ago

Data from 15 presentations will highlight the use of the platform for the treatment of pediatric and adult burn woundsVALENCIA,…

Humacyte Announces Date of Annual Shareholder Meeting

2 years ago

DURHAM, N.C., April 04, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable…

CareCentrix Serious Illness Care at Home Program Reduces Total Cost of Care, Hospitalizations

2 years ago

CareCentrix rebrands palliative offering as CareCentrix Serious Illness Care at HomeHARTFORD, Conn., April 04, 2022 (GLOBE NEWSWIRE) -- CareCentrix, a…

Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

2 years ago

- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - - Panel will discuss how TRACERx…

Digipath to Provide Product Testing for Redwood Cultivation Products, Including Mike Tyson’s New Ear Shaped Gummies, ‘Mike Bites’

2 years ago

LAS VEGAS, NV, April 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Digipath, Inc. (OTCQB: DIGP) (“Digipath” or the “Company”),…

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development

2 years ago

ALG-097558 demonstrates nanomolar potent antiviral activity and is up to 20-fold more active than nirmatrelvir in cell-based assays against multiple…

Lexicon Welcomes New Guidelines for the Management of Heart Failure

2 years ago

Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society of America New guidelines recommend…

CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis

2 years ago

NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and…

BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification

2 years ago

Certification Gives BioRestorative Therapies Clinical Grade Manufacturing Capabilities MELVILLE, N.Y., April 04, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the…